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Aims: In this study, we attempted to define a new histological staging and grading system 
to provide more information reflecting the clinical laboratory data and prognosis to 
hepatologists. Methods and Results: First, 17 histological lesions of primary biliary 
cirrhosis (PBC) were scored in 188 needle liver biopsy specimens. Factor analysis yielded 
three independent groups of factors: Factor 1 (fibrosis, fibrous piecemeal necrosis, orcein 
positive granules, bile plugs, Mallory bodies, feathery degeneration, bile duct loss and 
atypical ductular proliferation); Factor 2 (portal inflammation, eosinophilic infiltration, 
lymphoid follicle, epithelioid granuloma, interface hepatitis and chronic cholangitis); and 
Factor 3 (interface hepatitis, lobular hepatitis, acidophilic bodies and pigmented 
macrophages). Eight findings of Factor 1, but not Factors 2 and 3, were significantly 
correlated with the clinical laboratory data and scores of Mayo’s prognostic model. Factor 
1 lesions may reflect the histological progression (staging), while Factor 2 and 3 lesions 
may relate to necroinflammatory activities (grading). Then, we devised a staging and 
grading system using three lesions (bile duct loss, fibrosis and orcein positive granules) 
from Factor 1 and three from Factors 2 and 3 (chronic cholangitis, interface hepatitis and 
lobular hepatitis). This new system might provide more pathological information of PBC 
patients to hepatologists.  
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Introduction 
Primary biliary cirrhosis (PBC) is a chronic progressive liver disease of an unknown 
cause.1,2 Histologically, the interlobular bile ducts are selectively affected, presenting 
characteristic findings, such as chronic non-suppurative destructive cholangitis (CNSDC); 
such affected bile ducts disappear from the liver, and liver cirrhosis and failure finally 
develop.3-6 In addition to CNSDC, epithelioid granuloma and/or cholestatic findings in 
various degrees sometimes contribute to the histological diagnosis of PBC.7 The average 
time from diagnosis to end-stage liver disease ranges from several years to 20 years. As 
for a prognostic indicator, the serum bilirubin concentration is the best among all 
laboratory values. In addition, several mathematical models based on clinical and 
laboratory criteria have been proposed to predict disease progression.8,9
Histological staging systems of PBC have been proposed by Rubin et al.,10 
Scheuer,4,11 Popper and Schaffner,12 and Ludwig et al.13 In these staging systems, PBC is 
histologically classified into three or four stages. For example, according to Scheuer’s 
staging, stage 1 is referred to as the florid duct lesion or CNSDC. In stage 2, there is 
proliferation of the small bile ductules. Stage 3 is characterized by fibrosis or scarring. 
Stage 4 is cirrhosis. These histological stages reflect the progression of the disease from 
destruction of the intrahepatic bile duct to fibrosis and cirrhosis. These staging systems 
were mainly defined based on experiences of established liver pathologists. However, it is 
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well known that histological changes are heterogeneous in PBC livers and sampling 
errors are indicated in needle liver biopsies of PBC; histological lesions characterizing 
different stages could be seen on one liver biopsy and the staging may be different in liver 
biopsies obtained from different parts of the liver at the same time.3,4,14 These make the 
reproducible application of these staging systems difficult in some PBC cases. In addition, 
pre-existing systems were only for histological staging. Necroinflammatory changes in 
portal tract or parenchyma differ from case to case. It has not been clarified whether or 
not necroinflammatory features are related to the clinical characteristics, although the 
histological degrees of necroinflammation in PBC might be informative in the clinical 
field, the same as other liver diseases.15-18 Then, we tried to propose a staging and grading 
system for PBC using a scoring system of multiple histological features. This system 
seems to be more objective compared to pre-existing systems because of the scoring 
system of multiple histological features. In addition, using multiple histological features 
for staging or grading might contribute to the avoidance of sampling error in the 
histological evaluation of PBC livers.  
Since the publication of the latest staging system, that of Ludwig et al. in 1978,13 
much progress has been made in clinical areas, particularly in therapeutic fields.19-21 That 
is, a number of therapies for PBC have been attempted, although most of their efficacies 
have not been confirmed, except for ursodeoxycholic acid (UDCA) for classical PBC, and 
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combined UDCA and corticosteroid therapy for overlapping syndrome (PBC plus 
autoimmune hepatitis).22,23 
We propose herein a new histological staging and grading system, in which the 
combination analysis of three items reflects the histological progression toward cirrhosis 
and also the necroinflammatory activities of primary pathological changes. This new 
system may be useful in the evaluation of clinical situations of PBC patients. 
 
Patients and Methods 
Patient selection and diagnosis 
A total of 188 needle liver biopsy specimens from 188 patients who fulfilled the 
clinical, serological or histological criteria of PBC were evaluated in this study.1,2 The 
patients with known causes of liver diseases other than PBC were excluded. These 188 
liver biopsy specimens had been prepared consecutively at our university hospital and 
affiliated hospitals over the past 12 years. The specimens were immediately fixed in 
formalin and paraffin-embedded, then cut at 3μm thickness for hematoxylin-eosin, 
reticulin and orcein stainings. The orcein staining was used for the evaluation of the 
deposition of copper binding proteins in hepatocytes. All of these liver specimens 
contained at least 5 portal tracts. Histological examinations were performed by two 
people (KH and YN), evaluating 17 histological features that are elementary and 
Hiramatsu -7- 
representative for PBC (Table 1): fibrosis, portal inflammation, eosinophilic infiltration, 
lymphoid follicle, epithelioid granuloma in the portal tract, interface hepatitis, fibrous 
piecemeal necrosis, atypical ductular proliferation, orcein-positive granules, bile plugs, 
Mallory bodies, feathery degeneration, lobular hepatitis, acidophilic bodies, pigmented 
macrophages in the parenchyma, bile duct loss and chronic cholangitis, including 
CNSDC. Periportal pericellular fibrosis associated with hepatocellular swelling (cholate 
stasis) was called “fibrous piecemeal necrosis” in this study.3,24 Interface hepatitis 
corresponds to the lymphocytic piecemeal necrosis at the limiting plates.24 The criteria of 
scoring of these 17 individual lesions are shown in Table 1.  
The clinical data shown in Table 2 were available in all of these patients around the 
time of liver biopsy. These patients were not under specific therapy, such as UDCA, 
corticosteroids or D-penicillamine. The patient’s prognosis at the time of liver biopsy was 
predicted using the two previously reported methods, known as the original Mayo model 
and the updated Mayo model.8,9 In these models, histological findings are not counted. 
In the original Mayo model, a risk score (R) was computed, as follows: 
R= 0.871 x log e (bilirubin in mg/dl) -2.53 x log e (albumin in g/dl) + 0.039 x age 
in years + 2.38 x log e (prothrombin time in seconds) + 0.859 x edema 
The edema variable was coded as 0 for no edema and no diuretic therapy, 0.5 for 
edema present without diuretic therapy or edema resolved with diuretic therapy, and 1 for 
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edema despite diuretic therapy. Then, S(t) was computed for the patient’s probability of 
survival at least t years as follows: 
S(t ) = S0(t )exp(R-5.07) 
S0(t ) gives the survival probability for an individual with R= 5.07, which is the mean 
R from the combined data set of 418 Mayo patients. Using this model, the risk scores (R) 
of our 188 patients were computed. Furthermore, the risk scores (R) using the updated 
Mayo model were also computed.  
 
Factor analysis and correlational analysis of 17 histological lesions with clinical 
laboratory data  
First, to identify which histological lesions were related to each other, factor analysis 
was performed on 17 histological lesions (variables) after scoring. The factor analysis can 
examine the interrelations among all variables and identify groups of variables whose 
correlation with each other is greater than the variables in other groups. However, 
variables in a group were not completely independent from variables in other groups. 
Then, Spearman's rank-difference correlation coefficient was computed to test the relation 
between scores of histological findings with respect to factor analysis and clinical 
laboratory data, including age, alanine and aspartate aminotransferase (ALT and AST), 
alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (γ-GTP), total bilirubin, 
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albumin, γ-globulin, total cholesterol, prothrombin time, immunoglobulins (IgG, IgA, 
IgM), the antimitochondiral antiobodies (AMA) titer, the antinuclear antibodies (ANA) 
titer, and risk scores of the Mayo model or updated Mayo model. The histological 
lesion(s) correlated with the risk scores of the Mayo model are available for predicting 
the prognosis of PBC patients. The statistical study for histological and clinical and 
laboratory data was performed using software: StatView ver 4.5, Macintosh version (SAS 
Institute Inc., Cary, North Carolina, USA). They were regarded as significantly correlated 
when the correlation coefficient was <-0.3 or >0.3 and p<0.001. 
 
Application of the new staging and grading system to routine liver specimens of PBC 
Three pathologists (YZ, HA and SK) from three different hospitals attempted to apply 
the new staging and grading system (described in the discussion and result sections) to 36, 
41 and 52 needle liver biopsies of PBC from their laboratories (A, B and C), respectively.  
 
Results and Discussion 
Factor analysis of 17 histological lesions of PBC livers 
As shown in Table 3, factor analysis performed on 17 histological lesions (variables) 
yielded three independent factors (Factors 1, 2 and 3) under orthogonal (varimax) 
rotations. The variables, which were loaded at 0.50 or higher on a factor (at least 25% of 
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variance explained) in each factor are shadowed in Table 3. The percentage of the total 
variance of Factor 1 was 27.8%, and eight variables on it were loaded at 0.50 or higher. 
The percentage of the total variance of Factor 2 was 15.9% and six variables were loaded 
on it at 0.50 or higher. The percentage of the total variance of Factor 3 was 10.2% and 
four variables were loaded on it at 0.50 or higher. It is likely that the intercorrelation with 
the variables of the same factor were greater than those with the variables of other factors. 
In Factor 1, eight histological lesions (fibrosis, fibrous piecemeal necrosis, orcein 
positive granules, bile plugs, Mallory bodies, feathery degeneration, bile duct loss and 
atypical ductular proliferation) were clustered. They seem to be related to the cholestatic 
findings of the liver, and therefore seem to reflect the histological advancement of 
PBC.3-6 Fibrosis usually relates to the progression of chronic liver disease, and may 
mainly be due to prolonged chronic cholate stasis in the cases of PBC.3,5,6,21,24 Bile duct 
loss is the result of chronic destructive cholangitis with biliary epithelial apoptosis and is 
followed by the development of chronic cholestasis and then fibrosis.25,26 The other six 
lesions reflecting long-standing chronic cholestasis may be principally secondary to 
extensive bile duct loss. Longstanding chronic cholate stasis is generally associated with 
the subsequent loss of periportal hepatocytes and fibrosis. In this sense, the histological 
lesions of Factor 1 seem to be secondary lesions due to chronic cholangitis, and it seems 
reasonable that they are related to each other.  
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The relationship between the eight histological lesions in Factor 1 and the clinical or 
laboratory data were confirmed by statistical analysis (Table 4A). That is, all of these 
histological lesions were correlated with the total bilirubin, and the scores (R) of the 
original or up-date Mayo models. Especially, orcein positive granules were closely 
correlated with most clinical and laboratory data, including AST and ALT levels.  
Portal inflammation, eosinophilic infiltration, lymph follicle, epithelioid granuloma in 
the portal tract, interface hepatitis and cholangitis, including CNSDC were clustered in 
Factor 2; and interface hepatitis, lobular hepatitis, acidophilic bodies and pigmented 
macrophages were clustered in Factor 3. The lesions clustered in Factor 2 seemed to 
relate to portal inflammation and cholangitis, including CNSDC, while those in Factor 3 
related to parenchymal necroinflammation. Interestingly, no histological lesions clustered 
in Factors 2 and 3 were correlated with any of the clinical or laboratory data examined 
(Table 4B, 4C). In addition, these lesions did not correlate to the scores of the two Mayo 
models. These statistical analyses suggested that Factors 2 and 3 do not reflect the staging 
of PBC. This may be explainable by the long time span between chronic cholangitis and 
the histological progression of this disease in the liver and then the prognosis of PBC 
patients. Interface hepatitis and lobular hepatitis in PBC can be considered to relate to the 
necroinflammatory activities of PBC, and may not relate directly to the prognosis of PBC 
patients.22,27  
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While ANA is rather frequently detectable in the sera of PBC patients and a high 
titer ANA is used as a marker of PBC with evident autoimmune hepatitis (AIH) 
features,23,27 it was found in this study that there was no significant correlation between 
the ANA titer and the liver histology of PBC, bringing into question the 
immunopathogenetic roles of ANA in PBC.  
 
Proposal of a new histological staging and grading system for PBC 
Based on the above-mentioned results and discussion, we propose herein a new 
histological staging and grading system for PBC.  
Staging: The staging is useful for the evaluation of progression toward cirrhosis in any 
chronic liver disease. It is easy and convenient if only one representative lesion, such as 
the degree of fibrosis, is applicable to the histological staging of chronic progressive liver 
disease.15-17 However, in PBC with well-known notorious histological heterogeneity, 
more than one essential findings is recommended in combination to achieve a more 
reliable and objective evaluation of staging.3,4,21 It was found in this study that all of the 
eight histological findings clustered in Factor 1 were correlated with the clinical and 
laboratory data, particularly the prognostic scores of PBC patients. Thus, any of these 
lesions can be used as the item for the histological staging of PBC.  
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In this context, we adopted three lesions: fibrosis, bile duct loss and chronic 
cholestasis (deposition of orcein positive granules). Fibrosis is a common finding in 
various chronic progressive liver diseases and its degree is, in fact, used for the 
histological staging of chronic hepatitis and non-alcoholic steatohepatitis (NASH).15-17 
Bile duct loss is rather characteristic to PBC and is the result of immune-mediated biliary 
damage, and the degree of bile duct loss reflects the subsequent development of cholate 
stasis (Fig. 1A).28-30 Among the six cholestatic lesions (fibrous piecemeal necrosis, orcein 
positive granules, bile plugs, Mallory bodies, feathery degeneration, and atypical ductular 
proliferation), it was found in this study that orcein positive granules were significantly 
correlated with most of the clinicopathological data evaluated. In addition, the presence 
and amount of orcein positive granules are easily evaluable and detectable at relatively 
early stages of PBC if staining is successful (Fig. 1B), and they become more severe and 
extensive along the progression of this disease.31 Furthermore, the incidence of orcein 
positive granules is higher than those of Mallory bodies, bile plugs and feathery 
degeneration that become evident only at advanced stages. The criteria for atypical 
ductular proliferation and fibrous piecemeal necrosis are somewhat subjective, and are 
not easily evaluated by non-liver histopathologists and clinicians.4,24 So, we chose orcein 
positive granules as a representative histological lesion of chronic cholestasis. Thus, three 
items (fibrosis, bile duct loss and chronic cholestasis [deposition of orcein positive 
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granules]) constitute the baseline in the new staging system. However, great attention 
should be drawn to orcein staining. It has been recognized for many years that there are 
technical problems with orcein staining, depending very much on the synthetic nature of 
the dye and differing laboratory experience. Because considerable weight is attached to 
this stain in this system, histological evaluation of orcein staining should be carefully 
performed in the institutions not familiar with this staining method. Otherwise, the 
modified staging system without orcein staining (only fibrosis and bile duct loss) might 
be sufficient in those institutions. 
Scores for the degree of the three above-mentioned lesions are shown in Table 5. As 
for fibrosis (F), stage 0 means that there is almost no fibrosis or fibrosis limited to the 
portal tracts, stage 1 means fibrosis spreading beyond the portal area with incomplete 
septal fibrosis, stage 2 means the formation of completely connecting septal fibrosis with 
variable lobular distortion and stage 3 means cirrhosis (extensive fibrosis with 
regenerative nodules) (Fig. 1A). As for bile duct loss (B), stage 0 means no bile duct loss 
in any evaluable portal tracts. In stage 1 and stage 2, bile ducts loss is evident in less than 
1/3 of portal tracts and in 1/3 to 2/3 of portal tracts, respectively. In stage 3, the 
interlobular bile ducts were not seen in any evaluable portal tracts (Fig. 1A). As for 
chronic cholestasis (C) (orcein positive granules), stage 0 means no deposition in 
periportal hepatocytes. Stage 1 is characterized by deposition in less than one third of the 
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periportal hepatocytes of at least one portal tract, and stage 3 by the deposition in more 
than two thirds of the periportal hepatocytes along all the portal tracts or fibrous septa. 
Stage 2 is between stage 1 and stage 3 (Fig. 1B).  
In addition, three pathologists from different laboratories attempted to evaluate the 
total number of scores ranging from 0 to 9 in individual cases (Table 6A). Tentatively, we 
categorized these summed scores into 4 groups; group 1, 0 to 1 (minimal progression); 
group 2, 2 to 3 (mild progression); group 3, 4 to 5 (moderate progression), and group 4, 6 
to 9 (advanced progression). Interestingly, the distribution of PBC cases among the three 
laboratories was comparable to each other, suggesting that this system, using the total 
score of three histological items, seems to be applicable clinically. 
Grading (activities): The grading is applicable for the evaluation of the inflammatory 
activities of fundamental lesions of PBC. Ideally, the histological grading of PBC should 
reflect the fundamental lesions of PBC, and such histological lesions for grading should 
subside after successful treatment. In this system, we adopted three lesions (chronic 
cholangitis, including CNSDC, lobular hepatitis and interface hepatitis) for grading. They 
were chosen from Factors 2 and 3. Chronic cholangitis is known as the fundamental 
lesion of all PBC cases.3,10 PBC with evident features of interface hepatitis and lobular 
hepatitis is known as a hepatitic form of PBC or overlapping syndrome.3,23,27 In this sense, 
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interface hepatitis and lobular hepatitis can be used as a factor reflecting the 
necroinflammatory activities of a hepatitic form of PBC.  
Scores for the degree of the three above-mentioned lesions are shown in Table 5. As 
for chronic cholangitis, grade 0 means absent or ambiguous cholangitis. In grades 1, 2 
and 3, evident cholangitis is seen in less than 1/3, 1/3 to 2/3 and more than 2/3 of portal 
tracts, respectively. As for interface hepatitis, grade 0 means no interface hepatitis, while 
grades 1, 2 and 3 indicate the presence of interface hepatitis in less than 1/3, 1/3 to 2/3 
and more than 2/3 of portal tracts, respectively (Fig. 2A). As for lobular hepatitis, grade 0 
means no lobular hepatitis, while grades 1, 2 and 3 are characterized by mild and few 
focal necroses, multiple focal necrosis and zonal and/or bridging necrosis, respectively 
(Fig. 2B).  
Three pathologists from different laboratories attempted to evaluate this grading 
system in their cases, and the distribution of these activities is shown in Table 6B. The 
distributions seem comparable to each other, suggesting that this grading system may be 
applicable in general hospitals.  
We think that this staging and grading system may be useful to give evidence-based 
pathological information reflecting the clinical features or prognosis to hepatologists. 
However, prospective studies, such as clinical trials and statistical analyses using this 
system should be performed in future to verify the precision and relevance of this system. 
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It might be interesting to examine whether or not our scoring system reflects the kinds of 
different clinical courses or characteristics of PBC patients, such as rapidly advancing 
cases, asymptomatic cases, or AMA-negative cases. 
In conclusion, we proposed a new staging and grading system for the liver histology 
of PBC patients that can be applied to routinely stained histological sections, such as with 
hematoxylin and eosin, orcein, reticulin, or alternative staining for fibrosis. We 
recommend three items for staging to minimize the sampling errors inherent in PBC liver 
histology: fibrosis, bile duct loss and chronic cholestasis. We also recommend three 
histological lesions for the grading (activities) of PBC: chronic cholangitis, interface 
hepatitis and lobular hepatitis. While it may be a little burdensome for pathologists, we 
believe this method will provide a more objective evaluation of liver specimens of PBC 
to clinicians, and also provide new histological data in the study of drug therapy and in 
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Figure 1. Histopathology of the staging of primary biliary cirrhosis. A: The portal 
tract is fibrously enlarged and septal fibrosis is incomplete (stage of fibrosis, 1). 
While the portal vein (p) and hepatic arterial branches (arrow) are recognizable, the 
bile duct is lost in this portal tract and also in other portal tracts in this biopsy 
specimen (stage of bile duct loss, 3). H&E stain, x200. B: Deposition of 
orcein-positive granules (arrows) in the periportal hepatocytes is evident in this and 
other portal tracts (stage of chronic cholestasis, 3). A,B: Orcein stain, x200, serial 
sections of the same case. 
 
Figure 2. Histopathology of the grading of primary biliary cirrhosis. A: At the edge of the 
enlarged portal tract, interface hepatitis is clear in two thirds of the limiting plates (arrows, 
grade of interface hepatitis, 3). B: Multiple focal necroses are seen in the hepatic 
parenchyma (arrows, grade of lobular hepatitis, 2). A,B: H&E stain, x100. 
 24
Table 1. Evaluation of 17 histological lesions and criteria for their scoring in primary biliary cirrhosis 
Score Histological lesions 
0 1 2 3 
Fibrosis none or limited 






Portal inflammation Absent mild moderate severe 
Eosinophilic infiltration Absent mild moderate severe 
Lymphoid follicles Absent <1/3 of portal tract 1/3-2/3 of portal tract >2/3 of portal tract 
Epithelioid granuloma in portal tract Absent <1/3 of portal tract 1/3-2/3 of portal tract >2/3 of portal tract 
Interface hepatitis Absent mild moderate severe 
Fibrous piecemeal necrosis Absent mild moderate severe 
Orcein-positive granules Absent <1/3 of periportal area 1/3-2/3 of periportal area >2/3 of periportal area 
Bile plugs Absent <1/3 of periportal area 1/3-2/3 of periportal area >2/3 of periportal area 
Mallory bodies Absent <1/3 of periportal area 1/3-2/3 of periportal area >2/3 of periportal area 
Feathery degeneration Absent <1/3 of periportal area 1/3-2/3 of periportal area >2/3 of periportal area 
Lobular hepatitis Absent mild moderate severe 
Acidophilic bodies Absent mild moderate severe 
Pigmented macrophage Absent mild moderate severe 
Bile duct loss Absent <1/3 of portal tract 1/3-2/3 of portal tracts >2/3 of portal tracts 
Cholangitis including CNSDC Absent <1/3 of portal tract 1/3-2/3 of portal tracts >2/3 of portal tracts 
Atypical ductular proliferation Absent mild moderate severe 
CNSDC, chronic non-suppurative destructive cholangitis. 
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Table 2. Main clinical and laboratory data of 188 patients with primary biliary 
cirrhosis 
 
Patients Number (%) 
Total 188 
Female 162 (86.2%) 
Male 26 (13.8%) 
AMA or AMA-M2 Number (%) 
Positive 152 (80.9%) 
Negative 36 (19.1%) 
Clinical data Mean ± SD (normal range) 
Age (years) 56.5±11.1 
AST (IU/L) 74.1±100.7 (9-42) 
ALT (IU/L) 74.1±116.8 (2-39) 
γ-GTP (IU/L) 230±263.62(8-391) 
ALP (IU/L) 502.3±440.3 (86-272) 
Total bilirubin (mg/dl) 1.86±4.79 (0.2-1.3) 
Total protein (g/dl) 7.57±0.8 (6.6-8.1) 
Albumin (g/dl) 4.0±0.6 (3.9-4.9) 
Prothrombin time (second) 12.3±2.7 (10.5-11.5) 
γ-globulin (g/dl) 1.79±0.75 (0.6-1.3) 
IgG (mg/dl) 1972±640.8 (1300-1774) 
IgA (mg/dl) 376.4±175.9 (178-355) 
IgM (mg/dl) 541.8±309.7 (79-200) 
Edema score 0.03±0.18 
Original Mayo (R) 4.47±1.49 

























Table 3. Factor analysis of 17 histological lesions 
Histological findings Factor 1 Factor 2 Factor 3 
Fibrosis 0.835 0.006 0.189 
Portal inflammation -0.036 0.817 0.076 
Eosinophilic infiltration -0.249 0.598 0.129 
Lymphoid follicles 0.263 0.703 -0.064 
Epithelioid granuloma in portal tract -0.061 0.646 -0.06 
Interface hepatitis 0.088 0.574 0.501 
Fibrous piecemeal necrosis 0.778 -0.091 -0.034 
Orcein-positive granules 0.871 0.026 -0.071 
Bile plugs 0.714 -0.122 -0.161 
Mallory bodies 0.555 -0.018 -0.103 
Feathery degeneration 0.734 -0.095 -0.076 
Lobular hepatitis -0.152 0.323 0.667 
Acidophilic bodies 0.09 -0.093 0.772 
Pigmented macrophage 0.091 -0.002 0.542 
Bile duct loss 0.755 -0.065 0.074 
Cholangitis including CNSDC -0.16 0.831 0.087 
Atypical ductular proliferation 0.732 0.069 0.126 
% of total variance 27.8 15.9 10.2 
 
CNSDC, chronic non-suppurative destructive cholangitis; shadowed areas, highest loadings for 
each histological finding >0.50 (>25% of variance explained) are shadowed to facilitate 






Table 4A. Spearman's rank-difference correlation analysis between scores of each histological lesion of Factor 1 and clinical and laboratory data in primary 
biliary cirrhosis. 
Factor 1  








































































































































































































































































































Shadow areas, these coefficients were regarded as significantly correlated (shadowed) when the correlation coefficients (upper lane) is in -0.3> or 0.3< and 
P.<.001.(lower lane) AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; γ-GTP, gamma glutamyl transpeptidase; 
T-bil, total bilirubin; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies. 
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Table 4B. Spearman's rank-difference correlation analysis between scores of each histological lesion of Factor 2 and clinical and 
laboratory data in primary biliary cirrhosis 
 


































































































































































































































Abbreviations are same as those in Table 4A 
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Table 4C. Spearman's rank-difference correlation analysis between scores 
of each histological lesion of Factor 3 and clinical and laboratory data in 
primary biliary cirrhosis 



















































































































Abbreviations are same as those in Table 4A 
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Table 5. New histological staging and grading system for the liver or primary biliary cirrhosis 
 
Histological staging 0 1 2 3 




bridging fibrosis (complete 
septa) with lobular distortion 
cirrhosis (extensive fibrosis 
and regenerative nodules) 
Bile duct loss (B) absent  <1/3 portal tracts 1/3-2/3 portal tracts >2/3 portal tracts 
Chronic cholestasis (C) 
(orcein positive granules) 
absent <1/3 periportal areas 1/3-2/3 periportal areas >2/3 of periportal areas 
Histological grading 0 1 2 3 
Cholangitis (CH) absent or ambiguous 
cholangitis 
evident cholangitis in 
<1/3 portal tracts  
evident cholangitis in 1/3-2/3 
portal tracts 
evident cholangitis in >2/3 
portal tracts 
Interface hepatitis (IH) absent focal and mild moderate severe and extensive 










Table 6A. Distribution of summed score of three histological lesions (fibrosis, bile duct loss and chronic 
cholestasis*) in individual cases of primary biliary cirrhosis, and arbitrary categorization of summed scores 
into four groups in three different laboratories 
 Laboratory A (36†) Laboratory B (41†) Laboratory C (52†) 
 Summed Score 








(0 – 9) 
Group 
(1-4)‡ 





















6 3 5 5 
7 1 2 3 



















*, deposition of orcein positive granules; †, total number of cases examined in each laboratory; ‡, number of 





Table 6B. Distribution of the degree of three histological lesions (cholangitis, 
interface hepatitis and lobular hepatitis) reflecting the grading (activities) of primary 
biliary cirrhosis in three different laboratories 
 
 Laboratory A (36†) Laboratory B (41†) Laboratory C (52†) 
 Cholangitis   
0* 4 4 18  
1 18 24 23 
 2 10 13 10 
3 4 0 1  
Interface hepatitis   
 0 3 4 13 
1 24 22 28  
2 8 14 8  3 1 1 3 
 Lobular hepatitis   
0 0 5 0  
1 26 24 42 
 2 9 12 9 
3 1 0 1  
*, 0,1,2,3 is the degree of each lesion (described in the text.); †, total number of the 
cases examined in each laboratory 
 
 
 
 
 
 


